An observational study in Myopia and Myopia, Progressive, sponsored by Aller, Thomas A., OD. Status unknown at 1 site in United States. Open to participants aged 5 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by Aller, Thomas A., OD · Observational
Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.
Among the 342 studies in Myopia with a site in United States, this one is the 24th largest by planned enrollment of the 46 observational ones that give a count, is one of 16 that started in 2017, is one of 48 observational ones, and was the 163rd registered.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
Browse Myopia studies →27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ohio State University · Sites in United States
CooperVision International Limited (CVIL) · Sites in United States, Spain
Stanford University · Sites in United States
Jaeb Center for Health Research · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 5 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 15 · Phase 4 22
First in 1995; this study’s year is marked. 16 started in 2017.
This study's planned enrollment of 80 is below the median of 150 across 204 observational studies indexed under Myopia.
Median enrollment 68 across the 294 interventional studies, 91 across the 46 observational. Of the 279 that completed or were terminated, 175 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
204 of 342 have an industry lead sponsor. The 10 most frequent:
Aller, Thomas A., OD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Aller, Thomas A., OD has 2 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
13 of the studies in Myopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07679048Rochester Institute of TechnologyMeasuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos | 2026-12-15 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
Among the 342 studies in Myopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myopia has been increasing in prevalence and severity throughout the world over the last 30 years. Increasing levels of myopia are associated with increased frequencies and severity of various ocular pathologies, including cataracts, glaucoma, retinal detachments and other retinal pathologies and myopic maculopathy. Slowing myopia progression at a young age before the eye reaches excessive axial length may help to reduce the future risks of these ocular pathologies.
Conventional spectacles and contact lenses are prescribed correct myopia by moving the central focus of the eye for distance viewing from in front of the retina to on the retina centrally, or at the fovea. To varying degrees, these lenses allow the light to focus behind the retina, at varying peripheral retinal locations. These findings have led to efforts to design spectacle and contact lenses which correct peripheral hyperopic defocus, to reduce myopia progression.
The consensus theory for how both multifocal contact lenses and orthokeratology can control myopia progression is that they each can reduce, eliminate, or reverse relative peripheral hyperopic defocus. Existing published studies on the use of multifocal contact lenses to control myopia in humans have utilized lenses with the distance correction in the center with peripheral plus power to correct the peripheral blur. Until recently, there have been no daily disposable multifocal lenses in the US market with distance center designs.
The NaturalVue contact lens from Visioneering Technologies, Inc. is the first daily disposable distance center multifocal in the US. It has a novel extended depth of focus design where the distance correction is in the center of the optical zone, surrounded by a zone characterized by having a seamless, rapid transition from the distance power to a highly plus power at the edge of the optical zone.
This study will analyze the myopia progression of patients in the investigator's practice while wearing their habitual visual corrections for periods up to two years prior to being switched to NaturalVue contact lenses. They will then be followed for up to two years after beginning use of this novel lens design and the differences in their myopia progression after versus before this novel lens will be analyzed. Axial lengths will be measured with the IOLMaster after switching to NaturalVue, at six-month intervals and will be compared to axial lengths which have been collected with habitual corrections.
Myopia has been increasing in prevalence and severity throughout the world over the last 30 years. Increasing levels of myopia are associated with increased frequencies and severity of various ocular pathologies, including cataracts, glaucoma, retinal detachments and other retinal pathologies and myopic maculopathy. Slowing myopia progression at a young age before the eye reaches excessive axial length may help to reduce the future risks of these ocular pathologies.
Conventional spectacles and contact lenses are prescribed to correct myopia by moving the central focus of the eye for distance viewing from in front of the retina to on the retina centrally, or at the fovea. To varying degrees, these lenses allow the light to focus behind the retina, at varying peripheral retinal locations. These findings have led to efforts to design spectacle and contact lenses which correct peripheral blur to reduce myopia progression.
The consensus theory for how both multifocal contact lenses and orthokeratology can control myopia progression is that they each can reduce, eliminate, or reverse relative peripheral hyperopic defocus. Existing published studies on the use of multifocal contact lenses to control myopia in humans have utilized lenses with the distance correction in the center with peripheral plus power to correct the peripheral hyperopic defocus. Until recently, there have been no daily disposable multifocal lenses in the US market with distance center designs.
The NaturalVue contact lens from Visioneering Technologies, Inc. is the first daily disposable distance center multifocal in the US. It has a novel extended depth of focus design where the distance correction is in the center of the optical zone, surrounded by a zone with a seamless, rapid transition from the distance power to a highly plus power at the edge of the optical zone.
This study will analyze the myopia progression of patients in the investigator's practice while wearing their habitual visual corrections for periods up to two years prior to being switched to NaturalVue contact lenses. They will then be followed for up to two years after beginning use of this novel lens design and the differences in their myopia progression after NaturalVue versus before NaturalVue will be analyzed. Axial lengths will be measured with the IOLMaster after switching to NaturalVue, at six-month intervals and will be compared to axial lengths which have been collected with habitual corrections.
Study population will be drawn from the clinic of the principal investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
Device: NaturalVue Multifocal Contact Lens
NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
Refractive error changes
Changes in myopia over time will be characterized by the spherical equivalent refractive error as measured by manifest subjective refraction.
Time frame: Data will be collected at baseline and at every six months.
Axial length of the eye
Changes in the axial length of the eye will be measured with the Zeiss IOLMaster
Time frame: Data will be collected at baseline and at every six months.
Corneal curvature
Keratometry will be measured by the Zeiss IOLMaster
Time frame: Data will be collected at baseline and at every six months
Vitreous Chamber Depth
Vitreous Chamber Depth will be derived from measures of the Anterior Chamber Depth and the axial length as measured by the Zeiss IOLMaster.
Time frame: Data will be collected at baseline and at every six months.
Plan to share: No
Started Jan 2017 (actual). Primary completion is estimated for Jan 2022, 60 months after the start.
Of 87 non-industry observational studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's planned 60 months is above that.
Counting every sponsor, half of 96 studies reached it within 24 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.